Moderna’s Ambitious Growth Plans and Financial Complexities Lead to Hold Rating

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna, with a price target of $30.00.

Terence Flynn has given his Hold rating due to a combination of factors related to Moderna’s projected growth and financial strategies. The company has outlined ambitious growth drivers for the years 2026 through 2028, including new vaccine launches and geographic expansion. However, there are uncertainties regarding revenue projections, particularly as Moderna has not provided specific guidance for 2027 revenue despite acknowledging potential revenue of around $2.5 billion.
Additionally, while Moderna has taken steps to reduce operating expenses and improve gross margins, these efforts are balanced by the need for substantial cash investments and the management of post-marketing study costs. The company’s recent credit facility agreement provides financial flexibility, yet the overall financial outlook remains complex with several moving parts. These factors contribute to Flynn’s cautious stance, resulting in a Hold rating for Moderna’s stock.

In another report released today, Barclays also maintained a Hold rating on the stock with a $25.00 price target.